N-3 fatty acid supplementation mediates lipid profile, including small dense LDL, when combined with statins: a randomized double blind placebo controlled trial.

ABSTRACT:

Background

Epidemiological and clinical evidence suggests that high-dose intake of omega 3 fatty acids (n-3 FA) have a favorable role in altering serum triglycerides (TG) and non-high density lipoprotein cholesterol (non-HDL-C) when combined with statins in hyperlipidemic patients. Their efficacy in altering low-density lipoprotein cholesterol (LDL-C) particle size is yet to be established.

Aim

This study evaluated the effects of supplementing 4 g/day Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) on serum blood lipids, including small, dense LDL-C particle concentration, in hyperlipidemic patients receiving stable statin therapy.

Methods

In this randomized, placebo-controlled, double-blind parallel group study, 44 patients on statin therapy for > 8 weeks

SUBMITTER: Dogay Us G 

PROVIDER: S-EPMC9434850 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature